Ipsen's New Chief Outlines Growth Plans In U.S., Emerging Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
Tighter product focus and streamlined R&D will help double sales and triple profits by 2020, says CEO Marc de Garidel.
You may also be interested in...
Ipsen Moves Aggressively On U.S. Strategy, Builds Out Commercial and R&D Infrastructure
As part of an ongoing strategic reorganization, Ipsen announced the appointment of a nine-member U.S. leadership team to execute on the growth of its neurology and endocrinology franchises.
European Price Cuts, Restructuring Charges, Hit France's Ipsen in 2011
Ipsen's restructuring in France and the U.S, and European austerity measures, lead to a series of charges against 2011 profits, but drug sales increase 5% in the year.
In Seeking Focus, Ipsen Turns To Specialty Pharma Model
Marc de Garidel, Ipsen’s new CEO, is re-focusing the mid-sized French group’s attention on its core commercial assets, trimming the portfolio, and narrowing down early-stage R&D. The de-risking move turns Ipsen sharply in a specialty pharma direction that may please some investors over the near-term, but which raises questions related to the future viability of Ipsen’s R&D engine.